Karla Zadnik

Zhaoke Ophthalmology Announced First Patient Completes Three Year Enrollment in Phase III CHAMP Study of NVK-002

Retrieved on: 
Thursday, November 12, 2020

The CHAMP Study is an FDA drug trial that evaluates the ability of its lead compound, NVK-002, to slow the progression of myopia in children.

Key Points: 
  • The CHAMP Study is an FDA drug trial that evaluates the ability of its lead compound, NVK-002, to slow the progression of myopia in children.
  • It is currently under clinical evaluation in the CHAMP study and has entered Phase 3 clinical trial in the US and Europe.
  • CHAMP is a 576 subject, randomized, placebo-controlled, double-masked study evaluating the effects of NVK-002 on myopia progression in children.
  • Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd. is a wholly owned subsidiary of Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology"), which specializes in the development, manufacturing and marketing of ophthalmic drugs.

Zhaoke Ophthalmology Announced First Patient Completes Three Year Enrollment in Phase III CHAMP Study of NVK-002

Retrieved on: 
Thursday, November 12, 2020

HONG KONG, Nov. 12, 2020 /PRNewswire/ --Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd. ("Zhaoke Hong Kong") is pleased to announce today that the first patient has completed three year enrollment in the Phase III CHAMP (Childhood Atropine for Myopia Progression) study carried out by its partner, Nevakar Inc.("Nevakar").

Key Points: 
  • HONG KONG, Nov. 12, 2020 /PRNewswire/ --Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd. ("Zhaoke Hong Kong") is pleased to announce today that the first patient has completed three year enrollment in the Phase III CHAMP (Childhood Atropine for Myopia Progression) study carried out by its partner, Nevakar Inc.("Nevakar").
  • It is currently under clinical evaluation in the CHAMP study and has entered Phase 3 clinical trial in the US and Europe.
  • CHAMP is a 576 subject, randomized, placebo-controlled, double-masked study evaluating the effects of NVK-002 on myopia progression in children.
  • Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd. is a wholly owned subsidiary of Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology"), which specializes in the development, manufacturing and marketing of ophthalmic drugs.

iVeena Closes Series B Financing to Advance Multiple Programs in Clinical Development

Retrieved on: 
Tuesday, August 25, 2020

iVeena, a clinical stage biopharmaceutical company with products in development for unmet needs in ophthalmology, announces the successful completion of the Series B preferred stock bridge round.

Key Points: 
  • iVeena, a clinical stage biopharmaceutical company with products in development for unmet needs in ophthalmology, announces the successful completion of the Series B preferred stock bridge round.
  • These investments will be used to advance the clinical development programs for the treatment of keratoconus and pediatric high myopia and adult low myopia.
  • The Series B funds, along with the NEI grant, will enable iVeena to prepare for registration trials in keratoconus and initiate pilot studies in pediatric high myopia and adult low myopia, said Jerry Simmons, CEO.
  • iVeena is also developing IVMED-85 and IVMED-95 for the treatment of pediatric high myopia and adult low myopia respectively.